An understanding of cultural perspectives on medicine, such as the preference for injectables in Asia versus tablets elsewhere, is crucial for designing and positioning products for successful global launches. This insight often gets overlooked by scientifically-focused development teams.
Venture capital firm Sofinnova prioritizes hiring experienced pharma operators, even those with zero investment background. These experts provide invaluable hands-on guidance on drug development and commercialization to portfolio companies, contributing to a high rate of FDA product approvals.
The value of a late-stage asset is not just its scientific promise. Acquirers and investors look for a clear definition of unmet medical need, a straightforward clinical development pathway, and a well-defined regulatory landscape to de-risk the path to market.
Don't wait until after FDA approval to think about reimbursement. Smart biotechs engage with payers early and build payer-valued outcomes directly into Phase 2/3 trials. This creates a ready-made value dossier for payers alongside the regulatory submission package.
To capitalize on promising Chinese biotech assets while mitigating risks in IP and manufacturing (CMC), investors are creating new US-based companies ("NewCos"). This structure allows an experienced US leadership team and board to guide the asset's development to meet global regulatory standards.
Beyond current GLP-1 drugs that cause both fat and muscle loss, the next major opportunity in obesity treatment lies with therapies that selectively target fat while preserving or even rebuilding muscle mass. This addresses the significant downstream health risks of sarcopenia.
A physician's impact can scale dramatically in the pharmaceutical industry. While planning to return to clinical practice, Dr. Maha Radhakrishnan discovered her work in R&D and commercialization allowed her to impact over 85 million patients globally, far exceeding one-on-one care.